Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 15, 26 | Sachs Bruce I | director | A-Award | 93 | — |
| Oct 15, 26 |
| Garber Alan M |
| director |
| A-Award |
| 29 |
| — |
| Sep 8, 26 | Van Grunsven Jasper | officer: EVP, CP and NPPO | A-Award | 8,682 | — |
| Sep 8, 26 | Van Grunsven Jasper | officer | 0 | — |
| Aug 28, 26 | Ambrose Kristen | officer: SVP & Chief Accounting Officer | A-Award | 5,000 | — |
| Aug 27, 26 | Sachs Bruce I | director | G-Gift | 6,000 | — |
| Jul 21, 26 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | A-Award | 8,251 | — |
| Jul 21, 26 | Sachdev Amit | officer: EVP Chief Patient & Ext Af Off | A-Award | 8,251 | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 22, 2026 | 2026-10-22 16:10:59 | View |
| 3 | Oct 22, 2026 | 2026-10-22 16:06:03 | View |
| 8-K | Oct 20, 2026 | 2026-10-20 16:09:27 | View |
| 4 | Oct 19, 2026 | 2026-10-19 16:23:08 | View |
| 4 | Oct 19, 2026 | 2026-10-19 16:21:22 | View |
| 4 | Sep 10, 2026 | 2026-09-10 16:31:53 | View |
| 3 | Sep 10, 2026 | 2026-09-10 16:16:10 | View |
| 4 | Sep 1, 2026 | 2026-09-01 16:39:35 | View |
| 8-K | Sep 1, 2026 | 2026-09-01 16:25:14 | View |
| 4 | Aug 31, 2026 | 2026-08-31 16:20:11 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | VRTX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 29.0x | -17.8x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 26.9x | EPS est. 18.68 | In line |
| Price / Book | 6.3x | 5.9x | In line |
| Price / Sales | 10.1x | 9.1x | In line |
| EV / EBITDA | 22.4x | 56.7x | Discount |
| Return on equity | 23.3% | — | Top tier |
| Gross margin | 86.0% | 86.9% | In line |
| Debt / Equity | 0.10 | 0.10 | Conservative |
| Piotroski / Altman Z | 5/9 | Z 12.91 | Safe zone |
Discounted cash flow model
1255 daily bars · split adjusted
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Current price $501.95
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 8, 26 | RBC Capital | maintain | Outperform | Outperform |
| Sep 28, 26 | UBS | maintain | Buy | Buy |
| Aug 5, 26 | Truist Securities | maintain | Buy | Buy |
| Aug 5, 26 | Barclays | maintain | Overweight | Overweight |
| Aug 4, 26 | TD Cowen | maintain | Buy | Buy |
| Aug 4, 26 | Canaccord Genuity | maintain | Hold | Hold |
| Aug 4, 26 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Jul 13, 26 | UBS | maintain | Buy | Buy |
| Jul 13, 26 | Truist Securities | maintain | Buy | Buy |
Daily · Wilder smoothing
Classic floor pivots from 2026-10-19
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 45.19 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 42.44 | Oscillator | Neutral |
| Williams %R (14) | -60.85 | Oscillator | Neutral |
| MACD (12, 26, 9) | -5.46 (Hist -0.45) | Oscillator | Strong Sell |
| Average Directional Index (14) | 21.21 (+DI 17.5 / -DI 28.2) | Trend | Sell |
Stock news · updated daily
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details a.
Both of these ETFs look the part, but only one is truly the better buy for investors.
| EMA 20 | 507.92 | MA | Sell |
| SMA 20 | 509.73 | MA | Sell |
| EMA 50 | 510.10 | MA | Sell |
| SMA 50 | 522.66 | MA | Strong Sell |
| SMA 200 | 476.15 | MA | Strong Buy |
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 3, 2026 | 4.74 | 4.73 | Miss -0.2% | $3.33B |
| May 4, 2026 | 4.24 | 4.47 | Beat 5.4% | $2.99B |
| Feb 12, 2026 | 5.11 | 5.03 | Miss -1.6% | $3.19B |
| Nov 3, 2025 | 4.57 | 4.80 | Beat 5.0% | $3.08B |
| Aug 4, 2025 | 4.29 | 4.52 | Beat 5.4% | $2.96B |
| May 5, 2025 | 4.25 | 4.06 | Miss -4.5% | $2.77B |